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Table 1
Stem cell transplants in lymphoma
Type of SCT Disease Control
from Conditioning
Regimen
NRM Disease
Control
from GVL
Auto SCT Good Low None
RIC/NMA allo SCT Fair Moderate Yes
MAC allo SCT Good High Yes
Tandem auto-allo SCT Good Moderate Yes
MAC indicates myeloablative conditioning.
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and alternative donor transplantations. Although NRM
was signiﬁcantly higher in matched unrelated donor and
cord blood transplantations, the NRM for haploidentical and
matched sibling transplantations was similar [9]. Thus,
expanding the donor pool may allow more patients to
beneﬁt from this approach.
In summary, there are 4 different SCTmodalities available
for patients with high-risk lymphoma (Table 1). Careful pa-
tient selection, timing, considerations for disease control
before transplantation and incidence of NRMmay help select
1 modality over another. There is existing literature to sug-
gest excellent disease control and low NRMwhen auto SCT is
used for late relapsed DLBCL (relapse >12 months from
diagnosis) [3,4] and relapsed Hodgkin lymphoma in a posi-
tron emission tomographyenegative complete remission
after salvage therapy [10]. RIC allo SCT has been shown to be
very effective in controlling indolent lymphoma and the
incidence of NRM appears to be higher than auto SCT but
lower than myeloablative allo SCT [11]. Myeloablative allo
SCT has been shown to salvage a small fraction of chemo-
resistant lymphoma, although the beneﬁt could be offset by
high NRM. Finally, the current report from Chen et al. shows
that tandem auto SCT followed by RIC allo SCT can provide
excellent disease control due to cytoreduction followed by
GVL effect. The NRM with this sequential approach appears
to be similar to the NRM observed with RIC/NMA allo SCT
alone.Financial Disclosure: See Acknowledgments on page 1535.
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cytomegalovirus (CMV) infection on reconstitution of both
natural killer (NK) and T cell subsets is explored, stratifyingresults based on both CMV seropositivity and graft source.
CMV reactivation was associated with marked increases in
NK cell subsets bearing the CMV adaptive phenotype after
allogeneic hematopoietic stem cell transplantation (HSCT)
irrespective of graft source. The absence of adaptive
(NKG2Cþ/CD57þ) NK cells in CMV-seronegative recipients
who did not reactivate CMV further illustrates that survival of
this memory-like NK subset is dependent on the presence of
CMV antigen and/or chronic CMV infection. Moreover, this
study demonstrates that moremature sibling donor immune
cells impart some protection against reactivation of CMV
seropositive-recipients, even when the sibling donors are
CMV naive. To truly assess the role of NK cells in protection
against rechallenge/reactivation of viruses in the post-HSCT
setting, more clearly deﬁned markers of NK cell memory or
“memory-like function” in models of adaptive immunity is
R.H. Rouce / Biol Blood Marrow Transplant 21 (2015) 1533e1536 1535fundamental. This report begins to address some of these
questions.
NK cells are essential effector cells in the innate defense
against CMV. Attention has been drawn to an adaptive,
memory-like subset of NK cells that emerges after human
CMV (HCMV) infection. Several studies have conﬁrmed the
expansion of this NK subset in an antigen-dependent
manner reminiscent of the clonal expansion of adaptive
immune cells in response to HCMV infection [2,3]. The
adaptive or memory NK cell is deﬁned by expression of
high levels of the activating heterodimeric receptor CD94/
NKG2C. This NKG2Cþ NK cell subset commonly coexpresses
the terminal differentiation marker CD57, shown to play an
important role in the control of CMV, especially in the
postesolid organ, allogeneic, or umbilical cord blood
transplant period [4,5]. NKG2C and NKG2A are most often
mutually exclusive; thus, the overexpression of NKG2C
shifts the response to the nonclassical MHC class I molecule
HLA-E from inhibitory (as seen with a predominance of
NKG2AþNKG2C cells) to activating (with NKG2CþNKG2A
cells) [1]. Interestingly, although HCMV was the ﬁrst
pathogen shown to promote expansion of this NKG2Cþ NK
cell subset, similar observations have been made in other
viruses, including Hantavirus and HIV [6,7]. Of note,
expansion of this adaptive NK population in these viral
infections occurs only in patients who are also seropositive
for HCMV, suggesting these cells are the equivalent of
the memory-like NK cells expressing Ly49H observed in
CMV-infected mice [8].
The authors nicely conﬁrmed a predominance of the
inhibitory NK cell receptors KIR2DL2/3 within the NKG2Cþ
NK subset, which supports the premise that expansion of this
subset is linked to the presence or absence of certain killer
cell immunoglobulin-like receptor (KIR) in a particular MHC
class I environment. Interestingly, the authors demonstrated
that this adaptive memory-like phenotype could also be
induced in both CD56þ and CD56e T cells of CMV-
seropositive patients, especially those in whom the virus
was reactivated post-HSCT. Exposure to CMV antigens
resulted in expansion of a polyfunctional, cytokine-secreting
subset of T cells phenotypically analogous to the adaptive NK
population. This expanded population of KIRþCD3þCD56þ
T cells proved more cytotoxic than the KIR population and
was enriched for a CMV-pp65 speciﬁc TCR. As the authors
suggest, future evaluations of pp65-tetramer staining will
enhance our understanding of whether these CD57þ or
NKG2Cþ T cells mediate a direct CMV-speciﬁc immune
response or whether they activate the immune response
through interaction with NK cells or cytokine secretion.
Although not explored in this study, these same CMV-
reactive T cell clones have been shown to mediate anti-
cancer activity, suggesting a profound and potentially unique
impact of CMV on the adaptive immune system, one that
could likely be exploited in the post-HSCT setting [9].
More recent data suggest the NKG2C receptor is an active
participant in the immune response against HCMV rather
than ameremarker of a responding subset [10,11]. The broad
range of viruses shown to trigger the expansion of this subset
indicates that this phenomenon relies on an induced or
altered self-ligand rather than on a shared pathogen-derived
structure, as has been observed in some malignancies [11].
The upregulation of the HLA-E ligand in HCMV and other
viral infections [6,7] (and subsequent NK cell activation after
engagement of this ligand by NKG2C) supports this
hypothesis.As with T cells, CMV has developed immune evasion
strategies to avoid NK-mediated killing, such as the antago-
nistic effect of the main CMV protein pp65 on the natural
cytotoxicity receptor NKp30 [12]. Interestingly, the expres-
sion of the natural cytotoxicity receptors NKp30 and NKp46
are notably decreased in the subpopulation of NK cells that
coexpress CD57. Although CMV has been shown to down-
regulate DNAM-1 ligands on CMV-infected cells limiting
DNAM-1emediated activation of NK cells, elevated expres-
sion of DNAM-1 in CD57þ NK cells has been described.
Mouse studies suggest that the expression of DNAM-1 in
CD57þ NK cells contributes to the anti-CMV effect, which has
yet to be conﬁrmed in humans and warrants further study
[11,13].
The next obvious question raised by these intriguing
ﬁndings is whether these adaptive NK cells play a critical role
in other infections that reactivate in the post-HSCT period.
Hendricks et al. [14] reported a lack of expansion of the
NKG2ChiCD57þ NK cell subset in response to acute Epstein-
Barr virus infection, suggesting that emergence of this
adaptive NK population is not common to reactivation with
all herpes viruses.
Although the existence of these memory-like NK cells in
individuals infectedwith HCMV is undeniable, little is known
about how this pool is formed. Lee et al. [15] identiﬁed
several distinct subsets of memory-like NK cells, deﬁcient in
multiple transcription factors. Deﬁcient expression of these
proteins was largely conﬁned to the recently discovered
FcRg-deﬁcient NK cells that display enhanced antibody-
dependent functional activity. Importantly, these FcRg-deﬁ-
cient NK cells exhibited robust preferential expansion in
response to both HCMV and inﬂuenza-infected cells in an
antibody-dependent manner. These discoveries suggest that
the memory-like NK cell pool is shaped and maintained by a
mechanism that involves both epigenetic modiﬁcation of
gene expression and antibody-dependent expansion [15]
and warrant further study.
The discoveries described in this intriguing report do
more than challenge us to look beyond our conventional
views of NK cells as exclusivemembers of the innate immune
system: They raise the possibility of exploiting these adap-
tive NK and T cells for a number of purposes. These purposes
can include vaccine generation, adoptive immunotherapy, or
even as potential therapy for acute myelogenous leukemia
[16], considering reports that CMV reactivation is associated
with a reduced risk of post-HSCT relapse [17].
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